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Identity 
Other names: EC 3.1.3.n1; INPPL-1; SHIP-2; SHIP2; 
51C 
HGNC (Hugo): INPPL1 
Location: 11q13.4 
Local order: 71578250 FOLR1-FOLR2-INPPL1-
PHOX2A 71669874 (Entrez data). 
DNA/RNA 
Description 
The cDNA sequence for human SHIP2 is 3777 
nucleotide long (full processed mRNA is 4733 ntd 
long) (Hejna et al., 1995; Pesesse et al., 1997). The
coding region comprises 28 exons. There is evidence 
for the existence of a shorter transcript (372 ntd long of 
unknown significance coding for 123 amino acids. The 
C-terminus 74 codons (including the SAM-domain) are 
common for both the transcripts. 
Transcription 
SHIP2 promoter is regulated by Sp1 transcription 
factors (Ishida et al., 2005). Mechanisms of 
transcriptional regulations are unknown and perhaps 
not present. SHIP2 mRNA is expressed ubiquitously at 
high levels (Pesesse et al., 1997; Habib et al., 1998) and 
the protein levels are regulated post-transcriptionally by 
microRNA-205 (inhibitory) or microRNA-184 (which 
is a suppressor of mir-205) (Yu et al., 2008). 
Protein 
Description 
SHIP2 protein (1258 amino acids long) contains an 
inositol polyphosphate phosphatase domain (IPPc; aa 
422-735). In addition, SHIP2 has an amino-terminal 
SH2-domain (aa 21-117) and a carboxyl-terminal 
proline-rich region (Pro-rich; aa 935-1105). Also, 
SHIP2 contains a NPXY motif (aa 983-986) and a 
SAM (sterile alpha-motif) domain (aa 1201-1258). 
  
Structural features of SHIP2 protein: The positions of the SHIP2 catalytic domain and the protein interaction motifs are shown. 
Currently known SHIP2-interacting proteins are listed under the respective interaction domain/motifs. SH2 (src homology-2 domain), IPPc 
(inositol polyphosphate phosphatase catalytic domain), Pro-rich (proline rich region), SAM (sterile alpha-motif). 
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These structural elements provide sites for protein-
protein interactions which seem to play a major role in 
SHIP2 function. Several cellular proteins associate wi h 
SHIP2 via phosphotyrosine-dependent (SH2 or NPXY 
mediated) or proline-rich region (SH3 mediated) 
interactions (for a comprehensive list of interacting 
proteins and citations please see Prasad, 2009a). 
Expression 
Ubiquitously expressed with higher levels of mRNA in 
skeletal muscle, liver, adipose tissue, placenta and brain 
(Pesesse et al., 1997; Habib et al., 1998; Muraille et al., 
2001). Also expressed in B-cells, T-cells, platelets, 
mast cells and macrophages (Muraille et al., 1999; 
Dyson et al., 2003; Giuriato et al., 2003; Ai et al., 2006; 
Leung and Bolland, 2007). Protein levels are very low
in normal tissues and cells. Higher levels of protein 
expression are noted in many types of cancer cells 
(Wisniewski et al., 1999; Prasad et al., 2001; Prasad 
and Decker 2005) and in human breast cancer tissues 
(Prasad et al., 2008). SHIP2 protein levels in skeletal 
muscle and fat are higher in obese db/db mice as 
compared to normal heterozygous (db/+) mice and 
SHIP2 protein levels are moderately increased in 
response to a high-fat diet in normal mice (Hori et al., 
2002). SHIP2 genetic sequence in diabetic rats and 
humans contain mutations that may lead to increased 
levels of SHIP2 (Marion et al., 2002). 
Localisation 
SHIP2 is diffusely cytoplasmic but membrane 
enrichment of SHIP2 occurs during cell attachment 
(Prasad et al., 2001), membrane ruffling (Dyson et al., 
2001) or in response to m-CSF in macrophages (Wang 
et al., 2004). Mutation in the SH2-domain (R47G) 
causes punctate distribution pattern in the cytoplasm of 
HeLa cells (Prasad et al., 2001). SHIP2 has also been 
reported to localize to the nuclear speckles in vascul r 
smooth muscle cells (Deleris et al., 2003). 
Function 
Overview. Phosphoinositide (PI) lipids are important 
second messengers in the intracellular signaling 
pathways. PI lipids interact with the pleckstrin 
homology domain (PH-domain) containing cellular 
enzymes causing their membrane recruitment and/or 
allosteric activation. Phosphoinositide 3-kinase (PI3-
kinase) is central to the signal-induced generation of 
new phosphoinositides and its activation is a key 
intermediate step in the signaling initiated by various 
external signals including many hormones (insulin and
leptin), growth factors (EGF, IGF-1 and PDGF) as well 
as integrin ligation. SHIP2 dephosphorylates the 5-
position of phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) generated by the PI3-kinase, producing a new
second messenger PI-3,4-bisphosphate (PI-3,4-P2). As 
PI3-kinase pathway aberrations play a major role in the 
development of cancer, diabetes and inflammation, 
SHIP2 function is expected to be critically important 
for the molecular pathogenesis of these diseases. SHIP2 
also dephosphorylates PI-3,4-bisphosphate (Taylor et 
al., 2000). In vitro, a soluble inositol molecule, inositol-
1,3,4,5-tetrakisphosphate (IP4) also serves as a high
affinity substrate for SHIP2 (Pesesse et al., 1998; Chi et 
al., 2004; Batty et al., 2007). 
Negative Regulator of insulin signaling. In cell 
culture overexpression studies, SHIP2 acts a mild 
suppressor of insulin signaling (Sasaoka et al., 2001; 
Wada et al., 2001). RNA interference studies, however, 
contradict these observations (Zhou et al., 2004; Huard 
et al., 2007). SHIP2 null-mice are viable but resistant to 
high-fat-diet-induced obesity (Sleeman et al., 2005). 
Insulin signaling was enhanced only modestly in these 
mice. However, liver-specific suppression of SHIP2 
function in mice improves insulin function (Fukui et
al., 2005; Grempler et al., 2007). Mechanisms by which 
SHIP2 achieves the energy homeostasis therefore 
remain unclear at present. 
Negative Regulator of IGF-1 signaling. Exogenous 
SHIP2 in C2C12 skeletal muscle cells is shown to 
suppress IGF-1 signaling and to interfere with IGF-1-
induced muscle hypertrophy (Rommel et al., 2001). 
Similarly SHIP2 blocks compensatory hypertrophy 
upon its exogenous expression in rat skeletal muscle 
myocytes (Bodine et al., 2001).  
Positive Regulator of cytoskeleton remodeling, cell 
adhesion, lamellipodia formation/cell spreading. 
Transient exogenous expression of the wild type-SHIP2 
increases cellular adhesion in SH2-domain dependent 
manner in HeLa cells (Prasad et al., 2001). 
Furthermore, catalytic activity of SHIP2 is important 
for efficient lamellipodia formation and cell spreading 
(Prasad et al., 2001). Interaction with c-Met is 
important for this function of SHIP2 in MDCK cells 
(Koch et al., 2005). Also, C-terminus proline-rich 
region of SHIP2 is shown to be important for 
membrane ruffling process through its interaction with 
Filamin (Dyson et al., 2003). Src kinase-induced 
tyrosine phosphorylation of SHIP2 and consequent 
SHIP2-Shc association are important for HeLa cell 
spreading on type I collagen (Prasad et al., 2002). In 
MDA-231 breast cancer cells, SHIP2 promotes cell 
migration and this effect is associated to sustained 
EGFR-Akt signaling and increased expression of 
chemokine receptor CXCR4 (Prasad, 2009b). 
Negative Regulator of endocytosis (EGFR, 
Transferrin receptor, EphA2). Suppression of 
endogenous SHIP2 in cancer cells (HeLa cervical 
cancer cells and MDA-231 breast cancer cells) 
decreases ligand-induced endocytosis of the EGFR and 
EphA2 (Prasad and Decker, 2005; Zhuang et al., 2007). 
SHIP2 function in the endocytosis of EGFR is 
characterized by a direct and constitutive associati n 
between SHIP2 and c-Cbl ubiquitin ligase and changes 
in EGFR-Cbl association. Whereas SHIP2 directly 
interacts with EphA2 via SAM-domain and this 
interaction may be important for EphA2 endocytosis 
(Zhuang et al., 2007). SHIP2 associates with intersectin 
1, a major regulator of EGFR endocytosis, and recruits 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(5)  456 
it to the plasma membrane in response to EGF 
treatment (Xie et al., 2008). 
Regulator of Cell Cycle progression and apoptosis. 
Early studies indicated a positive association betwe n 
SHIP2 expression and cell proliferation where EGF 
increases the SHIP2 mRNA expression in thyrocytes 
(Pesesse et al., 1997). In addition, SHIP2 protein 
expression correlates with the EGFR expression in 
proliferating neurospheres (Muraille et al., 2001). 
Exogenous overexpression (using adenovirus vectors) 
of wild-type SHIP2 inhibits cell cycle progression i  
U87-MG glioblastoma cells (Taylor et al., 2000) and 
K562 leukemia cells (Giuriato et al., 2002) and of a 
dominant-negative SHIP2 (phosphatase-defective) 
increases proliferation of pancreatic beta-cells 
(Grempler et al., 2007). Whereas retroviral-mediate 
expression of SHIP2 does not inhibit cell cycle 
progression of Myeloma cells (Choi et al., 2002). 
Furthermore, RNAi-mediated suppression of 
endogenous SHIP2 in MDA-231 cells inhibits cell 
proliferation with G1 accumulation and decreased S-
phase and delays in vivo tumorigenesis (Prasad et al., 
2008). Retroviral-mediated expression of a catalytically 
inactive SHIP2 inhibits PDGF-induced proliferation f 
3T3-L1 preadipocytes (Artemenko et al., 2009). Thus, 
this aspect of SHIP2 function appears to be influenced 
greatly by the experimental approach and/or the cell 
types employed. 
Negative regulator of immune cell function. SHIP2 
inhibits Fcgamma Receptor IIa signaling including Akt 
activation and NF-kb-dependent gene trasncription 
(Pengal et al., 2003), downregulates Fcgamma 
Receptor-mediated phagocytosis (Ai et al., 2006) and
decreases mast cell degranulation (Leung and Bolland, 
2007; Saini et al., 2009). 
Homology 
SHIP2 is structurally related to SHIP1, another 
phosphoinositol 5-phosphatase expressed exclusively in 
hematopoietic tissues. SHIP1 is an important negative 
regulator of immune receptor and cytokine signaling. 
SHIP1 and SHIP2 show 64% identity in their inositol 
phosphatase domains and 54% identity in their SH2-
domains.  
 
The C-terminus proline-rich region carries the least 
similarity (also the SAM-domain is present only in 
SHIP2 and not in SHIP1) and appears to be the key for 
functional divergence between these two enzymes. In 
addition to the human gene, SHIP2 gene has been 
cloned from mouse, rat, cattle, dog, monkey, 
chimpanzee and zebra fish genomes. 
Mutations 
Germinal 
There is R1142C mutation within the Proline-rich 
region of SHIP2 in Goto-Kakizaki (GK rats; a model 
for type 2 diabetes) and spontaneously hypertensive 
(SH-) rats. This mutation slightly impairs insulin 
signaling in cell culture (Marion et al., 2002). 
Somatic 
In humans, a deletion in the SHIP2 3' untranslated 
region (UTR) has been identified in type 2 diabetic 
patients. In cell culture, this deletion enhances SHIP2 
promoter activity in reporter assays and SHIP2 over-
expression. This deletion is reported to be significantly 
associated with the presence of type 2 diabetes (Marion 
et al., 2002). 
Implicated in 
Chronic myelogenous leukemia (CML) 
Note 
SHIP2 is expressed at high levels in Bcr-Abl 
transformed K562 CML cells where it is highly 
tyrosine phosphorylated and constitutively associated 
with the adapter protein Shc in K562 leukemia cells 
(Wisniewski et al., 1999). Adenoviral-mediated 
exogenous overexpression of SHIP2 in K562 cells 
inhibits cell cycle progression (see 'Function - Cell 
cycle regulation' above). 
Breast cancer 
Note 
SHIP2 is overexpressed in many breast cancer cells 
when compared to non-transformed mammary 
epithelial cells (Prasad et al., 2008). Stable SHIP2 RNA 
interference in MDA-231 and MDA-468 breast cancer 
cells decreases cell proliferation (Prasad et al., 2008; 
Prasad, 2009b). SHIP2 suppression also causes delaye  
tumorigenesis in nude mouse mammary fatpad 
xenograft studies (Prasad et al., 2008). SHIP2 
overexpression is reported in clinical specimens of 
human breast cancers [n=65 (Prasad et al., 2008); and 
n=285 (Prasad et al., 2008)]. In invasive breast cancers 
(n=145), SHIP2 expression is positively correlated with 
reduced disease-free survival and estrogen receptor-
negative (ER-) and EGF receptor-positive (EGFR+) 
status (Prasad et al., 2008). 
Hepatocellular carcinoma 
Note 
SHIP2 expression in the cancer cells is decreased a 
compared to the adjacent normal cells of the same 
cancer specimens (n = 20) (Sumie et al., 2007). Any
possible association between the SHIP2 levels and 
glucose intolerance or the aggressiveness of the disease 
remains to be examined. 
Type 2 diabetes 
Note 
Single nucleotide polymorphisms (SNPs) in the SHIP2 
gene promoter and the 5' untranlated region correlates 
with the impaired fasting glycemia in Japanese 
population (Ishida et al., 2006). The haplotypes found 
more frequently in glucose intolerant people increase 
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transcription from SHIP2 promoter in reporter gene 
assays. 
Evidence from transgenic animal studies in mouse 
showed that SHIP2 function in liver is important for 
insulin-dependent glucose homeostasis (Fukui et al., 
2005; Buettner et al., 2007; Grempler et al., 2007; 
Kagawa et al., 2008).  
Metabolic syndrome. Single nucleotide 
polymorphisms (SNPs) and haplotypes of SHIP2 are 
significantly correlated with symptoms of the metabolic 
syndrome including hypertension in British and French 
people from type 2 Diabetes families (Kaisaki et al.,
2004). This association was not found with essential 
hypertension (not linked to metabolic syndrome) 
(Marcano et al., 2007). 
Obesity. Evidence from gene knockout studies in 
mouse showed that SHIP2 deletion caused resistance o 
high-fat diet induced obesity (Sleeman et al., 2005) 
although insulin signaling was only mildly enhanced. 
These studies raised the possibility that global 
inhibition of SHIP2 will be tolerated (not lethal) 
without significant side-effects. 
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